STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Carisma Therapeutics to Present at Upcoming Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

PHILADELPHIA, April 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present at the following upcoming conferences:

Needham 23rd Annual Virtual Healthcare Conference

  • Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.
  • Wednesday, April 10 at 3:45 PM ET
  • Virtual

Chardan 8th Annual Genetic Medicines & Cell Therapy Manufacturing Summit

  • Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.
  • Monday, April 29 at 2:00 PM ET
  • Virtual

Live webcasts will be available on the Company's Investor Events webpage. A replay of the webcasts, when available, will be archived for a limited time following each event.

About Carisma 

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com

Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-at-upcoming-conferences-302106448.html

SOURCE Carisma Therapeutics Inc.

Carisma Therapeutics Inc

NASDAQ:CARM

CARM Rankings

CARM Latest News

CARM Latest SEC Filings

CARM Stock Data

6.43M
30.73M
27.76%
19.81%
1.88%
Biotechnology
Pharmaceutical Preparations
Link
United States
PHILADELPHIA